Profile data is unavailable for this security.
About the company
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
- Revenue in USD (TTM)0.00
- Net income in USD-64.60m
- Incorporated2018
- Employees25.00
- LocationBelite Bio Inc12750 High Bluff Drive Suite 475SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 246-6240
- Websitehttps://belitebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Structure Therapeutics Inc (ADR) | 0.00 | -141.20m | 4.47bn | 220.00 | -- | 2.94 | -- | -- | -2.49 | -2.49 | 0.00 | 21.41 | 0.00 | -- | -- | 0.00 | -11.35 | -18.40 | -11.83 | -19.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.24 | -- | 185.66 | -- |
| Amicus Therapeutics, Inc. | 634.21m | -27.11m | 4.50bn | 511.00 | -- | 16.25 | -- | 7.10 | -0.0885 | -0.0885 | 2.05 | 0.8822 | 0.7311 | 0.4196 | 5.86 | 1,241,116.00 | -3.13 | -17.56 | -4.02 | -21.71 | 88.50 | 89.24 | -4.27 | -32.86 | 1.88 | 0.8051 | 0.5888 | -- | 20.05 | 19.44 | 51.68 | -- | 0.424 | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.52bn | 196.00 | -- | 17.94 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.76bn | 196.00 | -- | 6.93 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Alkermes Plc | 1.48bn | 241.66m | 4.87bn | 2.05k | 20.38 | 2.66 | 17.83 | 3.30 | 1.43 | 1.43 | 8.74 | 10.99 | 0.6498 | 1.04 | 4.08 | 719,950.80 | 10.64 | 10.11 | 13.68 | 13.22 | 86.69 | 84.10 | 16.37 | 15.06 | 3.19 | -- | 0.00 | 0.00 | -5.25 | 7.28 | -35.06 | -- | -0.8671 | -- |
| Celcuity Inc | 0.00 | -162.72m | 4.97bn | 87.00 | -- | 39.74 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| CG Oncology Inc | 4.04m | -161.00m | 5.11bn | 142.00 | -- | 6.49 | -- | 1,265.48 | -2.08 | -2.08 | 0.0523 | 9.33 | 0.0052 | -- | 5.50 | 28,450.71 | -20.82 | -- | -21.55 | -- | -16.31 | -- | -3,985.03 | -- | 24.58 | -- | 0.004 | -- | 254.70 | -- | -82.87 | -- | -- | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.44bn | 362.00 | -- | 5.51 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Protagonist Therapeutics Inc | 46.02m | -130.15m | 5.83bn | 132.00 | -- | 9.29 | -- | 126.60 | -2.04 | -2.04 | 0.7239 | 9.82 | 0.0651 | -- | 12.10 | 348,606.10 | -18.42 | -8.51 | -19.72 | -9.31 | -- | -- | -282.83 | -31.44 | -- | -- | 0.00 | -- | -89.41 | 9.96 | -147.29 | -- | 27.55 | -- |
| Cogent Biosciences Inc | 0.00 | -277.80m | 6.04bn | 258.00 | -- | 10.96 | -- | -- | -2.15 | -2.15 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -51.99 | -55.96 | -57.41 | -62.16 | -- | -- | -- | -- | -- | -- | 0.2594 | -- | -- | -- | -37.96 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -64.60m | 6.30bn | 25.00 | -- | 8.57 | -- | -- | -1.93 | -1.93 | 0.00 | 19.59 | 0.00 | -- | -- | -- | -13.85 | -23.54 | -13.94 | -24.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -114.73 | -- | -- | -- |
| Arcellx Inc | 22.29m | -228.93m | 6.67bn | 209.00 | -- | 16.42 | -- | 299.27 | -4.06 | -4.06 | 0.3945 | 6.95 | 0.0339 | -- | 7.31 | 106,631.60 | -34.81 | -28.60 | -42.17 | -34.05 | -- | -- | -1,027.26 | -274.64 | -- | -- | 0.00 | -- | -79.35 | -- | -113.26 | -- | 21.25 | -- |
| Kymera Therapeutics Inc | 39.21m | -311.35m | 7.05bn | 238.00 | -- | 4.45 | -- | 179.80 | -3.68 | -3.68 | 0.4642 | 19.42 | 0.0288 | -- | -- | 164,747.90 | -22.89 | -24.17 | -24.23 | -27.06 | -- | -- | -794.06 | -329.38 | -- | -- | 0.0021 | -- | -16.70 | 2.87 | -39.08 | -- | -30.75 | -- |
| Cytokinetics, Inc. | 88.04m | -784.96m | 7.48bn | 673.00 | -- | -- | -- | 84.94 | -6.53 | -6.53 | 0.733 | -5.37 | 0.0623 | -- | 5.12 | 130,815.80 | -55.55 | -49.49 | -64.23 | -55.60 | -- | -- | -891.60 | -897.66 | -- | -11.95 | 2.33 | -- | 376.56 | 9.54 | -33.15 | -- | 17.55 | -- |
| Nuvalent Inc | 0.00 | -425.38m | 7.88bn | 228.00 | -- | 6.28 | -- | -- | -5.85 | -5.85 | 0.00 | 15.96 | 0.00 | -- | -- | 0.00 | -33.30 | -27.97 | -35.31 | -29.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.13 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Belite Bio Inc's reporting currency: US Dollar USD
16.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Darwin Global Management Ltd.as of 31 Dec 2025 | 3.03m | 8.07% |
| RTW Investments LPas of 31 Dec 2025 | 715.33k | 1.91% |
| Millennium Management LLCas of 31 Dec 2025 | 558.88k | 1.49% |
| RA Capital Management LPas of 31 Dec 2025 | 432.48k | 1.15% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 414.24k | 1.10% |
| Eventide Asset Management LLCas of 31 Dec 2025 | 383.09k | 1.02% |
| Point72 Asset Management LPas of 31 Dec 2025 | 284.44k | 0.76% |
| Marshall Wace LLPas of 31 Dec 2025 | 192.70k | 0.51% |
| Medical Strategy GmbHas of 30 Dec 2025 | 143.56k | 0.38% |
| UBS Securities LLCas of 31 Dec 2025 | 94.30k | 0.25% |
More ▼
Data from 30 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
